Bacterial meningitis is an infection of the protective membranes surrounding the brain and spinal cord. These membranes, called meninges, become inflamed when bacteria enter the body and reach these spaces. Unlike viral meningitis, which is often less severe, bacterial meningitis is a medical emergency that can cause permanent disability or death within hours of symptom onset.
Learn About Paying Your FGUA Bill Online →
The infection spreads through respiratory droplets—the tiny particles released when an infected person coughs, sneezes, or talks. This means people in close contact with someone who has bacterial meningitis face the highest risk. The disease affects roughly 4,000 to 4,500 people annually in the United States, though this number has declined significantly since vaccines became available. Without treatment, bacterial meningitis kills about 15% of infected people. Even with antibiotics, 10-15% of survivors experience long-term complications including hearing loss, brain damage, or loss of limbs.
The most common bacterial culprits are Neisseria meningitidis (meningococcus), Streptococcus pneumoniae (pneumococcus), and Haemophilus influenzae type b (Hib). Each of these bacteria causes distinct patterns of disease and responds to different prevention strategies. Understanding which bacteria cause meningitis in your region and age group helps you make informed decisions about protection.
Prevention through vaccination and lifestyle measures works because it either stops bacteria from entering the body or strengthens the immune system's ability to fight infection before serious illness develops. Since bacterial meningitis progresses rapidly, prevention is far more effective than waiting for symptoms to appear.
Practical Takeaway: Bacterial meningitis is preventable through vaccination and basic precautions. Knowing the disease's seriousness helps you understand why public health agencies prioritize meningitis prevention for specific age groups and populations.
Meningococcal vaccines protect against Neisseria meningitidis, which causes roughly one-third of bacterial meningitis cases in the United States. The Centers for Disease Control and Prevention (CDC) recommends meningococcal vaccination for most adolescents and young adults, with different vaccine formulations addressing different serogroups of the bacteria.
Free Guide to Pay by Plate Illinois Billing →
There are two main types of meningococcal vaccines currently used: conjugate vaccines (MenACWY, brand names Menhibrix and Menveo) and serogroup B vaccines (MenB, brand names Bexsero and Prevnar). MenACWY vaccines protect against serogroups A, C, W, and Y, which together cause the majority of meningococcal disease in developed countries. MenB vaccines target serogroup B specifically, which causes roughly one-third of meningococcal disease in the United States and is increasingly common in college-aged populations.
The standard CDC recommendation for adolescents is a single dose of MenACWY at age 11 or 12, with a booster dose at age 16. This timing coincides with the routine adolescent vaccine visit and provides protection during the teenage years when meningococcal disease risk increases. Young adults who missed this vaccination during adolescence should talk with their healthcare provider about catch-up vaccination through age 21.
MenB vaccination follows a different schedule. The CDC recommends MenB vaccination for all adolescents and young adults ages 16-23, with individual risk considerations for those up to age 30. Unlike MenACWY, there is no universal booster recommendation for MenB after the primary series, though some high-risk individuals may benefit from additional doses. College students living in residential housing, military recruits, and people with certain medical conditions should discuss MenB vaccination with their doctor regardless of age.
People with specific health conditions require meningococcal vaccination regardless of age. These include individuals with weakened immune systems, asplenia (absence of a functioning spleen), persistent complement deficiencies, and those taking certain medications that affect immunity. Additionally, people traveling to countries where meningococcal disease is common—particularly those visiting the meningitis belt in sub-Saharan Africa during dry season (November to May)—should receive appropriate meningococcal vaccination before travel.
Practical Takeaway: Review your vaccination history or your child's records to see whether meningococcal vaccines have been received. If you're between 16 and 23, or if you fall into a higher-risk category, discuss your meningococcal vaccination status with a healthcare provider to determine which vaccines you need.
Streptococcus pneumoniae (pneumococcus) causes approximately one-third of all bacterial meningitis cases in the United States, making pneumococcal vaccination a critical prevention tool. Unlike meningococcal disease, which peaks in adolescence, pneumococcal meningitis affects both young children and older adults, with infants under age 5 facing the highest risk from invasive pneumococcal disease.
Free Guide to Mold Removal Methods for Walls →
Pneumococcal vaccines have undergone significant changes in recent years as new formulations have become available. Currently, two main types of pneumococcal vaccines are used: pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV). Pneumococcal conjugate vaccines create stronger immune responses and work better in younger children and people with weakened immune systems. The newest pneumococcal conjugate vaccine, Prevnar 20, protects against 20 strains of pneumococcus and represents a major advancement in pneumococcal prevention.
Infants and young children receive a series of pneumococcal conjugate vaccines as part of routine childhood vaccination. The standard schedule involves doses at ages 2 months, 4 months, 6 months, and 12-15 months. This early vaccination is essential because infants have immature immune systems and cannot fight pneumococcal infection effectively on their own. Catching up on missed doses remains possible through age 5, though the schedule depends on the child's age when vaccination begins.
Older children and adults who did not receive pneumococcal vaccination as infants may still benefit from vaccination depending on their age, health status, and medical history. Adults age 50 and older, and younger adults with chronic diseases like heart disease, lung disease, diabetes, or weakened immunity, should discuss pneumococcal vaccination with their doctor. People who have had their spleen removed or who have certain genetic immune deficiencies require pneumococcal vaccination regardless of age.
The introduction of Prevnar 20 has simplified pneumococcal vaccination for many adults. Previously, a two-vaccine sequence was recommended for older adults (PCV13 followed by PPSV23), but Prevnar 20 may provide broader protection with fewer doses. However, vaccination recommendations continue to evolve as new evidence emerges, so speaking with a healthcare provider about your individual situation provides the most current guidance.
Practical Takeaway: Ensure children receive pneumococcal vaccines on schedule starting at age 2 months. If you're an adult with chronic health conditions or age 50 or older, discuss pneumococcal vaccination with your doctor to determine your vaccination needs based on your personal health profile.
Before the Haemophilus influenzae type b (Hib) vaccine became available in 1985, Hib meningitis was the leading cause of bacterial meningitis in children under age 5 in the United States. Between 1930 and 1985, thousands of children developed this disease annually, with roughly 10-30% mortality rate and even higher rates of permanent neurological damage among survivors. The introduction of the Hib vaccine represents one of public health's greatest successes, reducing Hib meningitis cases by more than 90% within a decade.
How to Delete Your Fitbit Account Guide →
Today, Hib meningitis is rare in the United States because routine childhood vaccination against Hib has been standard practice for nearly 40 years. The Hib vaccine is part of combination vaccines that also protect against other diseases, making it convenient to administer alongside other routine childhood shots. Infants receive Hib vaccine at ages 2 months,
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.